Navigation Links
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
Date:11/24/2008

KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented today at the company's 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.

The dose-finding study was a randomized, placebo-controlled, double-blind, multicenter, multinational clinical trial that evaluated the efficacy and safety of four different doses (1, 2, 5 or 10 mg BID) of preladenant compared to placebo in the treatment of patients with moderate to severe Parkinson's disease with motor fluctuations and dyskinesias. All patients were on a stable regimen of standard treatments with L-DOPA and other adjunctive treatments, such as dopamine agonists and/or entacapone, but were still experiencing motor fluctuations and dyskinesias. The previous treatment was continued throughout the trial, in which the study medication was given as an adjunctive therapy.

A total of 253 patients were randomized into the trial, with the treatment phase lasting 12 weeks. Preladenant was statistically significantly more effective than the control group at the doses of 5 and 10 mg BID, respectively, in reducing the "off"-time, the primary endpoint of the trial.

In addition, preladenant significantly increased the "on"-time at the same doses of 5 and 10 mg BID, a secondary endpoint of the study. Importantly, this improvement in "on"-time was not associated with a proportional overall increase in dyskinesias. Preladenant was found to be safe and well tolerated.
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
2. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
3. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
4. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
5. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
6. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Schering-Plough Reports Top-Line Results of the IDEAL Study
11. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation ... release its second quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, August ... quarter and other business developments. Interested parties ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)...  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... of our Medicare resources and continue highlighting the success of the prescription drug benefit, ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
(Date:8/1/2015)... ... August 01, 2015 , ... Western University of Health ... that comprises a growing percentage of U.S. physicians, and reflects the diversity of ... part of the message delivered by John W. Becher, DO, president of the ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the ... of their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has ... both companies have agreed to join their missions of purpose together to change the ...
(Date:8/1/2015)... ... ... reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... including ones already sent. , While text messaging has more features than it did ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... ... 2015 , ... Last week, the Mesothelioma Applied Research Foundation ... accessed by visiting http://www.curemeso.org/store . , “Our new store features a variety ... a product is purchased, the Meso Foundation receives a $5.00 donation,” said Beth ...
Breaking Medicine News(10 mins):Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading ... venous reflux disease, today,announced the appointment of Peter Osborne ... Administration., Mr. Osborne joins VNUS with over 25 ... Osborne had served as the Company,s,Interim CFO since October ...
... 3 times weekly may increase risk, study suggests , , ... a Mediterranean diet rich in fish, fresh fruits and vegetables, ... their children against asthma and allergies, new research suggests. , ... included 468 mother and child pairs that were followed from ...
... Matters of the mind can affect matters of the heart. ... researchers has found that major anxiety and/or depression, can double ... This is one of the first studies to focus on ... were hospitalized for events such as a heart attack. , ...
... be saved , , FRIDAY, Jan. 18 (HealthDay News) -- If ... die from sudden cardiac arrest could be dramatically reduced. , ... calling for renewed efforts to teach CPR and to find ... the lifesaving technique. , "There is a tremendous opportunity for ...
... Jan. 18 LifeSync Corporation is,pleased to announce ... of Operations. Ms. McLane comes to LifeSync Corporation ... Johnson Company, where she,most recently held the position ... joining Cordis, Ms. McLane spent over 13,years at ...
... brain tumors, dual implantation of radioactive seeds and ... a study led by specialists at the Neuroscience ... University Hospital. , The study, published in the ... that patients treated with simultaneous implantation of radioactive ...
Cached Medicine News:Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Mediterranean Diet for Mom Fends Off Asthma, Allergies in Kids 2Health News:Depression and anxiety can double chances of heart ailments 2Health News:Heart Association Renews Call for CPR Training 2Health News:Heart Association Renews Call for CPR Training 3Health News:LifeSync Corporation Appoints Nancy McLane as Senior Vice President Operations 2Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2
... Physiological lesion assessment using Fractional ... proven and cost effective solution ... location of stenosis). Radi's new ... offer fast, easy and accurate ...
... the perfect partner for growing your business ... scalable to meet your needs now and ... your Allura Xper FD20 system supports mixed-use ... to new technologies allows you to add ...
... not slices, changes the way anatomy is ... LightSpeed VCT Series of scanners combine superior ... of difficult patients or procedures more routine., ... the door to new procedures while improving ...
... designed to maximize patient comfort and deliver ... ever to feature Vacuum Pump Deflation Technology. ... reduces the "slamming" effect commonly associated with ... maintains patients comfort and security while treatment ...
Medicine Products: